Trial Profile
A randomised phase II trial of CVA 21 for the treatment of malignant melanoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2014
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Mar 2014 New trial record
- 08 Nov 2013 This trial is expected to start in the second half of 2014, according to a Viralytics media release.